- Home
- DLTH vs HURA Comparison
DLTH vs HURA Comparison
Compare DLTH & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLTH
- HURA
- Stock Information
- Founded
- DLTH 1989
- HURA 2009
- Country
- DLTH United States
- HURA United States
- Employees
- DLTH N/A
- HURA N/A
- Industry
- DLTH Clothing/Shoe/Accessory Stores
- HURA
- Sector
- DLTH Consumer Discretionary
- HURA
- Exchange
- DLTH Nasdaq
- HURA Nasdaq
- Market Cap
- DLTH 121.1M
- HURA 131.8M
- IPO Year
- DLTH 2015
- HURA N/A
- Fundamental
- Price
- DLTH $2.81
- HURA $2.45
- Analyst Decision
- DLTH Buy
- HURA Strong Buy
- Analyst Count
- DLTH 1
- HURA 2
- Target Price
- DLTH $7.00
- HURA $11.50
- AVG Volume (30 Days)
- DLTH 64.5K
- HURA 185.5K
- Earning Date
- DLTH 12-04-2025
- HURA 11-14-2025
- Dividend Yield
- DLTH N/A
- HURA N/A
- EPS Growth
- DLTH N/A
- HURA N/A
- EPS
- DLTH N/A
- HURA N/A
- Revenue
- DLTH $602,746,000.00
- HURA N/A
- Revenue This Year
- DLTH N/A
- HURA N/A
- Revenue Next Year
- DLTH $0.24
- HURA N/A
- P/E Ratio
- DLTH N/A
- HURA N/A
- Revenue Growth
- DLTH N/A
- HURA N/A
- 52 Week Low
- DLTH $1.58
- HURA $1.80
- 52 Week High
- DLTH $4.66
- HURA $7.20
- Technical
- Relative Strength Index (RSI)
- DLTH 40.37
- HURA 48.06
- Support Level
- DLTH $2.66
- HURA $2.25
- Resistance Level
- DLTH $3.06
- HURA $2.58
- Average True Range (ATR)
- DLTH 0.20
- HURA 0.11
- MACD
- DLTH -0.05
- HURA 0.02
- Stochastic Oscillator
- DLTH 20.00
- HURA 65.48
About DLTH Duluth Holdings Inc. Class B
Duluth Holdings Inc is an apparel brand in the United States. The company offers shirts, pants, and casual wear for men and women under brands like Alaskan Hardgear, Armachillo, Ballroom, Cab Commander, Crouch Gusset, Dry on the Fly, Duluth Trading Co, Duluthflex, Fire Hose, Longtail T, No Polo Shirt, No Yank, Wild Boar, and others. The Company's revenue consists of the sale of apparel, footwear, and hard goods. The company operates in a single operating segment.
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.